Back to the Corporate Site
Veloxis

Press Releases

Veloxis Increases Share Capital in Connection with Exercise of Warrants

December 1, 2017 at 6:00 AM EST

Company Release no. 24/2017

 

To: NASDAQ Copenhagen A/S                                  Copenhagen, Denmark, 01 December 2017

  

Veloxis Increases Share Capital in Connection with Exercise of Warrants

 

Veloxis Pharmaceuticals A/S announces that the Company's capital has been increased by 1,444,900 new shares with a nominal value of DKK 0.10 each corresponding to nominally DKK 144,490 as a consequence of the exercise of warrants by former employees of the Company granted under the Company's warrant program.

As a result of the employee's investment in the Company proceeds to Veloxis Pharmaceuticals A/S from the capital increase amounts to DKK 520,164.

The subscription price for the new shares is DKK 0.36 per share of nominal DKK 0.10.

The new shares will be listed on NASDAQ Copenhagen following registration of the capital increase with the Danish Business Authority, upon which the share capital of Veloxis Pharmaceuticals A/S will be DKK 171,243,853.10 divided into shares of DKK 0.10 each.

Each share of nominal DKK 0.10 carries one vote at general meetings in Veloxis Pharmaceuticals A/S.  The new shares give rights to dividend and other rights from the time of registration of the capital increase with the Danish Business Authority.

  

For more information, please contact:

Craig A. Collard            

President & CEO                      

Phone: +1 919 591 3090                     

Email: cac@veloxis.com                      

 

About Veloxis Pharmaceuticals

Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients.  A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals, Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA.  Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the Company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs.  The Company is focused on the direct commercialization of Envarsus XR in the U.S., expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.  For further information, please visit www.veloxis.com.

 

The information contained in this section of Veloxis Pharmaceuticals A/S (the "Company") website is not intended for, and must not be accessed by, or distributed or disseminated, directly or indirectly, in whole or in part, to persons resident or physically present in the United States of America (including its territories and possessions, any state of the United States and the District of Columbia, the "United States"), Canada, Australia and Japan, or any jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction, and does not constitute an offer to sell or the solicitation of an offer to buy or acquire, any ordinary shares or other securities of the Company in the United States, Canada, Australia, Japan or any jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction.

The shares of the Company referred to on this website (the "Shares") have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. There is no intention to register any Shares referred to herein in the United States or to make a public offering of the Shares in the United States.

The Shares have also not been and will also not be registered under the applicable securities laws of Canada, Australia or Japan. There will be no public offer of the Shares in Canada, Australia or Japan.

Access to the information and documents contained on the following websites may be illegal in certain jurisdictions, and only certain categories of persons may be authorized to access such information and documents. All persons who wish to have access to the documents contained on this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website, or require registration or approval for any acquisition of securities by them. The Company assumes no responsibility if there is a violation of applicable law and regulations by any person.

I therefore certify that:

1. I am resident and physically present outside the United States, Canada, Australia and Japan;

Yes No

2. I am resident and physically present outside the United States, Canada, Australia and Japan and, in that case, I am authorized to access the information and documents on this website without being subject to any legal restriction and without any further action required by the Company;

Yes No

3. I have read, understand and agree to comply with all of the restrictions set forth above.

Yes No

Access to this information is limited to authorized persons who are resident and physically present in other jurisdictions outside the United States, Canada, Australia and Japan.

The information contained in this section of Veloxis Pharmaceuticals A/S’ website is restricted and is not for release, publication or distribution, directly or indirectly, in whole or in part in, into or from the United States of America (including its territories and possessions), any state of the United States and the District of Columbia, Canada, Australia and Japan or any jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction.